UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2003
NEKTAR THERAPEUTICS
(Exact name of Registrant as specified in its charter)
Delaware 0-23556 94-3134940
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
150 Industrial Road
San Carlos, California 94070
(Address of principal executive offices and Zip Code)
Registrant's telephone number, including area code: (650) 631-3100
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
Exhibit 99.1: Press Release Dated April 22, 2003
Item 9. Regulation FD Disclosure
This Form 8-K is being furnished to report information pursuant to Item 12
"Results of Operations and Financial Condition." Please see Item 12 below.
Item 12. Results of Operations and Financial Condition
On April 22, 2003, Nektar Therapeutics issued a press release announcing results
for the quarter ended March 31, 2003. A copy of the press release is attached as
Exhibit 99.1 to this Current Report and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
By: /s/ AGIT S. GILL
-----------------------------------
Ajit S. Gill
Chief Executive Officer,
President and Director
Date: April 22, 2003
By: /s/ AJAY BANSAL
-----------------------------------
Ajay Bansal
Chief Financial Officer, and Vice
President, Finance and
Administration
Date: April 22, 2003
EXHIBIT INDEX
Exhibit No. Description
99.1 Earnings Press Release of Nektar Therapeutics dated April 22,
2003.